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INTRODUCTION:  Gastro  Intestinal  Stromal  Tumor  (GIST)  is  the most  common  mesenchymal  tumor  of  the
gastrointestinal  tract  (GI).  GIST  that  arises  primarily  outside  the  GI tract  is  termed  Extragastrointestinal
Stromal  Tumor  (EGIST).  To  the  best  of our  knowledge,  few  cases  of EGIST  in  the  abdominal  wall were
reported.
PRESENTATION  OF  CASE:  We  present  a  rare case  of  EGIST  in  the abdominal  wall  of a 57 year-old  female
patient.  The  asymptomatic  tumor  was  located  in the  superior  aspect  of  the  left  rectus  abdominis  mus-
cle, measured  5.4 × cm  5.3  × cm  6.9  cm  and  was  well  circumscribed.  Histological  examination  showed  an
epithelioid  cell  morphology.  The  mitotic  count  was  7/50  HPFs.  Immunohistochemistry  showed  diffuse
strong  CD117  positivity,  focal  positivity  for S100.  The  tumor  was  excised  and  the  margins  were  free  of
malignancy.  The  patient  was  doing  well  postoperatively  and  was  discharged  on  STI-571 regimen.
DISCUSSION:  Although  GIST  is  the most  common  mesenchymal  tumor  of  the  gastrointestinal  tract,  a  case
with EGIST  in  the  abdominal  wall  is  rare.  Positive  immunohistochemical  staining  for CD117  is a  deﬁning
feature  of  GISTs.  A great  percentage  of EGISTs  represent  a metastasis  from  a primary  GIST. In our case,
the clinical  and diagnostic  work-up  have  been  proved  it to be  an  EGIST.
CONCLUSION:  The  existing  data  on EGIST  is insufﬁcient  to make  a  ﬁnal  conclusion  regarding  the malignant
potential  and clinicopathological  factors  of  EGISTs  that determine  patient  prognosis.  Thus  a follow-up
for  a long  period  is required.  EGISTs  should  be kept  in mind  in  the  differential  diagnosis  for  patients
presenting  with  solid  mass  of the abdominal  wall.
gical © 2011 Sur
. Introduction
Gastrointestinal Stromal Tumors (GISTs) are a subset of GI
esenchymal tumors of varying differentiations. Previously, these
umors were classiﬁed as GI leiomyomas, leiomyosarcomas,
eioblastomas and schwannomas as a result of their histologi-
al ﬁndings and apparent origin in the muscularis propria layer
f the intestinal wall. However, GISTs now are recognized as a
istinct group of mesenchymal tumors due to its immunohisto-
hemical and ultra structural characteristics. GISTs express c-kit
rotein also known as CD117, which is considered as a highly spe-
iﬁc marker that differentiates it from other mesenchymal tumors
uch as leiomyomas.1
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Extragastrointestinal Stromal Tumors (EGISTs) are a rarely
reported group of tumors2 that arise outside the GI but histologi-
cally resemble their GI counterpart. Approximately 80% are located
in the omentum or mesentery, and the remainder develops in the
retro peritoneum.3–5 To the best of our knowledge, a few cases were
reported with an EGIST in the abdominal wall.6
2. Case report
A 57 year old female with no signiﬁcant past medical or surgical
history presented to the general surgery clinic chieﬂy complaining
of painless abdominal mass which had gradually increased in size
over a period of 3 years. Besides the increase in size, she reported no
other particular symptoms associated with the mass. The abdom-
inal examination revealed a ﬁrm, non-pulsatile, and smooth mass
that was  ﬁxed in the epigastric region.
Open access under CC BY-NC-ND license.As the mass was  felt to be not simply subcutaneous, a com-
puterized tomography (CT) scan was  obtained, which revealed
a well deﬁned, lobulated, heterogeneously enhanced soft tissue
mass with ﬂecks of calciﬁcation and necrosis originating from
 BY-NC-ND license.
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Fig. 1. Axial enhanced CT scan of abdomen showing heterogeneously enhancing
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cobulated soft tissue mass with ﬂecks of calciﬁcation and necrosis originating from
he  superior aspect of left rectus abdominis muscle and bulging posteriorly, causing
ndentation on left liver lobe.
he superior aspect of left rectus abdominis muscle, measuring
5.4 × cm 5.3 × cm 6.9 cm). Although the mass was shown to cause
ocal indentation onto the left liver lobe, there was no evidence of
nvasion or underlying peritoneal inﬁltration (Fig. 1). Our preoper-
tive differential diagnosis included desmoid tumor and soft tissue
arcoma.
Routine blood test results were unremarkable. Chest X-ray
howed no lung parenchyma or bone lesion, CT scan of the abdomen
howed no evidence of metastasis, liver lesion or presence of other
asses. The esophagogastroduodenoscopy (EGD) was  performed
ostoperatively and showed that esophagus, stomach, pylorus,
uodenal bulb, and the duodenum to the third portion were normal.
ine Needle Aspiration (FNA) was of low yield in the pre opera-
ive diagnosis. Excision was done through a 4 cm incision placed
ver the mass and revealed a large, white tan, rubbery mass not
ttached to intraperitoneal structures (Fig. 2). The margins were
ent for frozen section and came back as negative for malignancy
nd recovery was uneventful.
ig. 2. Gross specimen showing lobulated soft tissue mass containing ﬂecks of cal-
iﬁcation.Fig. 3. Immunohistochemical analysis showed diffuse strong CD117 positivity for
both cytoplasmic and membranous components.
Histopathological examination of the specimen showed a well
circumscribed lobulated mass with surrounding ﬁbrous capsule
and pushing borders made up of proliferation of epitheliod cells.
The mass showed perivascular cohesion with loss of cohesive-
ness away from the blood vessels. There were cells shaped round
to polygonal with variably eosinophilic and clear cytoplasm and
vesicular chromatin and some prominent nucleoli. Average mitotic
count was that of 7 mitoses per 50 high power ﬁelds (HPFs).
Immunohistochemical analysis showed diffusely strong CD117
positivity for both cytoplasmic and membranous components
(Fig. 3) and focal positivity for S100, while it was completely
negative for Vimentin (which might be negative in 5% of
cases with GISTs), cytokeratin, CD34 (which can be observed
in 25% of cases with GISTs), neuron speciﬁc enolase (NSE),
CD99, desmin, and myogenine, so the histopathological diag-
nosis was  that of epithelioid GIST. Molecular genetic analysis
for c-KIT was  not available at our institution with limited
resources.
Post operatively, the patient was  doing well and discharged on
STI-571 regimen. After 5 months of follow-up, no recurrence or
metastasis was  detected by clinical or radiological exams.
3. Discussion
Gastrointestinal Stromal Tumors (GISTs) are the most common
mesenchymal tumors of the GI tract,7 many of which are identi-
ﬁed in the ﬁfth or sixth decades.8 They can occur at any site along
the GI tract but mainly occur in the stomach or small intestine,
with a smaller percentage in other locations.9 The pathogenesis
is a gain of function mutations in the c-KIT gene which results in
over expression of the KIT receptor also called CD117 or stem cell
factor receptor. The counterpart that arises outside the gastroin-
testinal tract was termed as Extragastrointestinal Stromal Tumor
(EGIST) by Reith et al.10 The majority of EGISTs (14 cases) that were
re-classiﬁed by Agaimy and Wünsch was found to be either GISTs
with extensive extramural growth resulting in loss of contact to
the external muscle coat of the gut (8/14) or as a metastasis from
an inoperable GIST (2/14) or from a previously resected decep-
tively benign tumor (1/14). Thus, a great percentage of EGISTs
appeared to be due to metastasis from a primary GIST.11 In our
case, the diagnostic workups, including CT scans and endoscopies
proved that the mass was likely to be a genuine EGIST. In addition,
other ﬁndings suggestive of EGIST were the features of immuno-
histochemical staining, and the large size of the asymptomatic
tumor.
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EGISTs were also reported in pleura, omentum, mesentry, pan-
reas and abdominal wall. Thalheimer et al. reported an EGIST of
bdominal wall in a 40-year-old patient with 24 cm-sized tumor
ith low mitotic index (1/50 HPFs), in which tumor cells showed
ositivity for CD117, CD99, CD34, Vimentin, and actin.12
The diagnosis of GIST was established based on the morphol-
gy and immunophenotyping. Histologically, there are three types
f GISTs: spindle celled (70%), epithelioid (20%) and mixed.13
he tumor in our case showed epithelioid type histology and
as immunopositive for c-KIT. Approximately 95% of GISTs
arry an activating somatic mutation of CD117.11 CD117 is the
roduct of proto-onco-gene c-KIT, a tyrosine kinase transmem-
rane receptor located on chromosome 4 (4q11-q12).15 Positive
mmunohistochemical staining for CD117 is a deﬁning feature of
ISTs14; however there are GISTs that have a mutation of PDGFRA
nstead of c-kit and therefore they do not show the character-
stic CD117 positive immunostaining. C-kit positive tumors are
ost responsive to the treatment with c-kit selective tyrosine
inase inhibitor, STI-571; some reports support a therapeu-
ic trial of STI-571 for all GIST patients regardless of CD117
xpression.14
Other neoplasms, in which CD117 expression is detected, such
s melanoma and others,16 can be differentiated by its characteris-
ic morphology with immunohistochemical analysis. This case has
egative smooth muscle and neuronal markers with total negativ-
ty for CD34 and Vimentin, resulting in exclusion of most of these
ifferential diagnoses. However, with a simple immunohistochem-
cal method optimized for clinical use, desmoid can be regarded
s a c-Kit-negative tumor.17 In our case, desmoid tumor diagnosis
as excluded due to the epithelioid morphology and the pushing
ature of borders as well as the pattern of CD117 immunostaining
s it cytoplasmic and membranous, while desmoid tumors express
ytoplasmic positivity only. Also desmoid tumor has CD117 positiv-
ty either focal or diffuse typically expressed more weakly than in
IST,18 in addition desmoid tumors are characterized by a spatially
omogeneous proliferation of wavy spindle cells without atypia,
ssociated with collagen deposition (often of the keloidal type), and
n inﬁltrative border rather than pushing borders as in our case.19
The National Institute of Health (NIH) developed a new classiﬁ-
ation system for risk of malignant behavior in 2001, which ranged
rom very low risk to high risk and was based on tumor size and
itotic count.16 In general, tumors larger than 5 cm,  with more than
 mitoses per 50 HPFs are considered to be high risk. In our case,
he tumor size was (5.4 × cm 5.3 × cm 6.9 cm), with mitotic count
f 7 per 50 HPFs, so it was considered a high risk tumor.
. Conclusion
The existing data on EGIST is insufﬁcient to make a ﬁnal
onclusion regarding treatment, prognosis and recurrence. Thus
ollow-up for a long period of time is required. Also EGISTs should
e kept in mind for the differential diagnosis in patients presenting
ith solid mass of the abdominal wall.
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